Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of etranacogene dezaparvovec in adults with severe or moderately severe hemophilia B
NL-OMON59998Phase 3Completed
- Sponsor
- CSL Behring
- Start
- Jan 2019
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of etranacogene dezaparvovec in hemophilia B (HB), sponsored by CSL Behring. Primary endpoint: Annualized bleeding rate non-inferiority comparison. Started Jan 2019; status: completed.
02
Drugs
etranacogene dezaparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NL-OMON59998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59998.